• Molecular NameOxyphenbutazone
  • Synonym1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione; 1-p-Hydroxyphenyl-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine; 1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine; 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl; 4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione; 4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione; 4-Butyl-2-(4-hydroxyphenyl)-1-phenyl-3,5-dioxopyrazolidine; 4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione; Hydroxyphenylbutazon; OPB; Ossifenbutazone [dcit]; Oxifenbutazona [inn-spanish]; Oxifenylbutazon; Oxiphenbutazone; Oxiphenbutazonum; Oxyphenbutazonum [inn-latin]; Oxyphenobutazone; Oxyphenylbutazone; P-hydroxyphenylbutazone; P-oxyphenylbutazone; Usaf Ge-14
  • Weight324.38
  • Drugbank_IDN/A
  • ACS_NO129-20-4
  • Show 2D model
  • LogP (experiment)2.72
  • LogP (predicted, AB/LogP v2.0)2.5
  • pka4.7 (22)
  • LogD (pH=7, predicted)-0.05
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.61
  • LogSw (predicted, AB/LogsW2.0)0.2
  • Sw (mg/ml) (predicted, ACD/Labs)0.09
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds5
  • TPSA60.85
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA metabolite of phenylbutazone.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)0.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life~3 days
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A